VIA EDGAR CORRESPONDENCE
August 25, 2022
United States Securities and Exchange Commission
Office of Trade & Services
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Ms. Taylor Beech
|Re:||bioAffinity Technologies, Inc.|
|Registration Statement on Form S-1, File No. 333-264463|
|Registration Statement on Form 8-A, File No. 001-41463|
|WITHDRAWAL OF REQUEST FOR ACCELERATION OF EFFECTIVENESS|
Dear Ms. Beech:
Reference is made to a letter filed by bioAffinity Technologies, Inc. (the “Company”) as correspondence via EDGAR on August 24, 2022, in which the Company requested that the effectiveness of the above-captioned Registration Statements on Form S-1, as amended, and Form 8-A, as amended, be accelerated to 4:30 p.m., Eastern Daylight Time, on Thursday, August 25, 2022, in accordance with Rule 461 under the Securities Act of 1933, as amended.
The Company is no longer requesting that such Registration Statements be declared effective at this time and hereby formally withdraws its requests for acceleration of that effective date.
If you have any questions regarding this withdrawal, please contact the Company’s outside counsel, Wilhelm E. Liebmann of Dykema Gossett PLLC at (210) 554-5414.
|Very truly yours,|
|BIOAFFINITY TECHNOLOGIES, INC.|
|By:||/s/ Maria Zannes|
|Title:||Chief Executive Officer|